CDK4 and neutropenia: The PRAEGNANT study did not specify which cyclin-dependent kinase 4 and 6 inhibitor was used, but the data were similar to those of other studies, with neutropenia, leukopenia, diarrhoea, and asthenia being the most frequent adverse effects.